The WACC of Aarey Drugs and Pharmaceuticals Ltd (524412.BO) is 15.0%.
| Range | Selected | |
| Cost of equity | 13.60% - 16.50% | 15.05% |
| Tax rate | 23.40% - 25.60% | 24.50% |
| Cost of debt | 10.30% - 28.00% | 19.15% |
| WACC | 12.6% - 17.3% | 15.0% |
| Category | Low | High |
| Long-term bond rate | 7.5% | 8.0% |
| Equity market risk premium | 6.9% | 7.9% |
| Adjusted beta | 0.88 | 1.01 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 13.60% | 16.50% |
| Tax rate | 23.40% | 25.60% |
| Debt/Equity ratio | 0.21 | 0.21 |
| Cost of debt | 10.30% | 28.00% |
| After-tax WACC | 12.6% | 17.3% |
| Selected WACC | 15.0% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 524412.BO:
cost_of_equity (15.05%) = risk_free_rate (7.75%) + equity_risk_premium (7.40%) * adjusted_beta (0.88) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.